Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine

Investors are fixated on a burgeoning market of companies developing treatments for baldness, following the recent success of drugs aimed at combating obesity. The obesity drug industry's triumph has led Wall Street to eye a new, more aesthetic problem: pattern hair loss, which affects millions of people in the United States. Since the late 1990s, there have been no new approved medications for this condition, prompting a surge in interest for innovative solutions.

Veradermics (MANE) has seen its stock price surge nearly 500% since going public in February, while Absci's shares have more than doubled so far in 2026. Cosmo NV also reported positive results for an experimental male hair-loss treatment, though its stock has been affected by the dominance of U.S. competitors. For those ineligible for hair transplant surgery or unable to afford it, the primary options have been over-the-counter topical minoxidil (Rogaine) or prescription finasteride (Propecia), both with their own set of side effects.

Minoxidil can cause heart palpitations, whereas finasteride is known to reduce sex drive. Wall Street views these new treatments as an untapped goldmine, with consumers eager to pay out-of-pocket for more effective options. The parallels drawn with the GLP-1 weight-loss drug boom highlight the potential profitability of this emerging market.